Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

2,606

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

February 26, 2026

Study Completion Date

February 26, 2026

Conditions
Gonococcal Infection
Interventions
BIOLOGICAL

Meningococcal Group B Vaccine

A combination vaccine consisting of rMenB and OMV NZ.

OTHER

Placebo

150mM sodium chloride (0.9% saline solution).

Trial Locations (13)

10027

Harlem Prevention Center, Columbia University, Mailman School of Public Health, New York

10330

The Thai Red Cross AIDS Research Centre, Bangkok

10400

Armed Forces Research Institute of Medical Sciences - Royal Thai Army Clinical Research Center, Bangkok

19104

University of Pennsylvania HIV/AIDS Prevention Research Division, Philadelphia

20889

Walter Reed National Military Medical Center, Bethesda

30303

Emory University School of Medicine - The Ponce de Leon Center, Atlanta

30308

Emory University Hospital Midtown - Emory Clinic Infectious Diseases, Atlanta

35294

University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham

60612

University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago

70119

LSU - CrescentCare Sexual Health Center, New Orleans

90035

UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles

94102

SFDPH Bridge HIV Center, San Francisco

Unknown

Malawi Clinical Research Site, Lilongwe, Lilongwe

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH